GTx's enobosarm fails Phase II for stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat stress urinary incontinence. Among the 493 postmenopausal women enrolled in the double-blind, U.S. trial, neither of two doses of enobosarm led to a significantly higher proportion of patients with a >50% reduction in incontinence episodes per day, the primary endpoint, vs. placebo after 12 weeks (57.7% for 1 mg and 58.9% for 3 mg vs. 52.7% for placebo). Enobosarm is a non-steroidal selective androgen receptor modulator (SARM).

GTx has little else in its pipeline. By year end, the company said it hopes to identify selective androgen receptor degrader (SARD) development candidates to treat castration-resistant prostate cancer (CRPC)...